Business Wire

SULZER

Share
Sulzer: Threefold Increase in Dispensing Rates, and Treatment of Sensitive Materials

Sulzer’s newly developed Blueline cartridge system is designed specifically for the application of highly viscous materials, with a view to enhancing end users’ productivity. Blueline delivers a threefold increase in dispensing rates compared with conventional cartridge systems. It is compatible with commonly used dispensers and will be unveiled at the JEC World 2017 exhibition in Paris.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170314005752/en/

Sulzer Mixpac AG – a subsidiary of Sulzer Ltd., a global leader in the manufacture and supply of liquid application and mixing technology products and services – will showcase its innovative new Blueline cartridge system at JEC World 2017 in Paris.

Dispensing rates up to three times higher

Highly viscous materials push existing cartridge systems to their limits in terms of the achievable dispensing rate. Previously, users would have to make do with small quantities of such materials or switch to considerably more complex mechanical processing of adhesives. Available with 2:1 and 10:1 mixing ratios, the Blueline cartridge system opens up a host of new possibilities.

Applications in aircraft and vehicle construction, general industry and the building sector

Marco Frei, Head Sales Industry EMIRA at Sulzer Mixpac AG, explains: “Blueline extends the range of possible applications for cartridges , allowing end users to boost productivity. Compared with existing systems, it offers considerably higher dispensing rates when applying highly viscous materials. The large cross-sections of the outlets combined with new, optimised mixing geometry increases dispensing rates up to threefold compared with currently available cartridge systems – and all this with the same dispensing force. The interface design features separate outlets from the cartridge to the mixer, removing the risk of unintentional mixing and clogging of the cartridge outlet by material components. This translates into clean and reliable processing of two-component materials.”

Quick, safe and clean processing of sensitive 2-K materials

Honeycomb core and edging filler are applied in two-component (2-K) form in sectors such as aircraft construction. These materials have densities of less than 1g/ml and are formed by adding hollow plastic or glass spheres, which helps to reduce weight. When processing such materials, high pressure and high shear rates cause these spheres to burst, making them unusable. In addition, these materials are also highly viscous, and in some cases there are differences in compressibility between the two components. For these reasons, the options for processing such materials using cartridge systems were previously extremely limited. The new Blueline system changes all this – it opens up a host of totally new possibilities, allowing for the rapid, safe and clean processing of sensitive 2-K materials with the help of cartridge systems.

JEC in Paris

The JEC trade fair is the world’s largest composites exhibition, making it the ideal platform for Sulzer Mixpac to introduce its Blueline system and showcase its entire range of dispensers and cartridge-based application systems.

Blueline – key facts

  • For highly viscous materials that are difficult to apply
  • For high dispensing rates (threefold increase in dispensing quantity)
  • For materials sensitive to pressure and shearing
  • Compatible with commonly used MIXPAC dispensers

Sulzer Mixpac at JEC World 2017

Paris Nord Villepinte Exhibition Centre, hall 6, stand A62

Link to Press Kit

Contact:

Sulzer
Gerald Fleisch
Head of Marketing Sulzer Mixpac, Sulzer Mixpac Ltd
Tel: +41 (0)81 772 2164
gerald.fleisch@sulzer.com

Link:

ClickThru

Social Media:

https://www.facebook.com/SulzerMixpacUKLtd

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MSCI Announces Baer Pettit to Retire as President17.11.2025 13:00:00 CET | Press release

Additional senior leadership changes will drive growth in new client segments and products MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that C.D. Baer Pettit, President and Chief Operating Officer (COO), and a member of the Board of Directors, has informed the company that he will retire next year after more than 25 years in senior leadership roles. Mr. Pettit will continue to serve as President and a Director until March 1, 2026, and will remain as an advisor to the company for a period of time to ensure a smooth transition. Mr. Pettit joined MSCI in 2000 and has served in numerous senior leadership roles, including heading Client Coverage, Marketing and Index. He was appointed COO in 2015 and President in 2017, overseeing all products and operations, and he joined the Board of Directors in 2023. “Baer has been my longtime business partner, and he has played a pivotal role in shaping MSCI’s st

AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth17.11.2025 13:00:00 CET | Press release

Dr Lee is a seasoned biopharmaceutical executive with a proven track record of leading cross-functional teams to successfully develop and commercialize innovative therapies in oncology AdvanCell Pty Ltd (“AdvanCell”), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief Executive Officer and member of the Board of Directors. Dr Lee will head AdvanCell’s US expansion, accelerating clinical, manufacturing, and partnership activities to advance lead clinical candidate 212Pb-ADVC001 and the company’s innovative radiopharmaceutical portfolio. She will assume her role from January 1, 2026, and will be based at the company’s new US headquarters near Boston/Cambridge, MA. “Philina brings a rare combination of global commercial leadership, deep radiopharmaceutical expertise, and an outstanding record of building high growth organizations and high-performance teams,” said Andrew Kay, C

Connections, Local Flavors, and Luxurious Experiences Top the 2026 Bacardi Cocktail Trends Report17.11.2025 13:00:00 CET | Press release

This year’s findings highlight a move towards more meaningful occasions, micro-indulgence, and storytelling cocktail experiences The five defining trends set to reshape cocktail culture and the spirits industry in 2026 are highlighted in the seventh annual Bacardi Cocktail Trends Report. The Report released by Bacardi Limited, the largest privately held international spirits company, in partnership with The Future Laboratory (TFL), draws on data from Bacardi-led and third-party research, consumer surveys, bartender interviews and TFL’s trend forecasting to uncover the forces shaping cocktail experiences, flavor innovation, and drinking culture in the year ahead. The Report also reveals the cocktails which are set to be the most popular in 2026 and trends for younger Legal Drinking Age (LDA) consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117678098/en/ The 7th annual Bacardi Cocktail Trends Report unveils what an

Arada to Acquire Majority Stake in £2.5bn Thameside West Development, Unlocking One of London’s Largest and Most Connected New Waterfront Neighbourhoods17.11.2025 12:58:00 CET | Press release

Arada, the UAE’s fastest-growing master developer, announces that it has agreed the acquisition of an 80% stake in Thameside West, a landmark waterfront mixed-use development located at the western end of London’s Royal Docks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117374964/en/ HH Sheikh Sultan bin Ahmed Al Qasimi, Chairman of Arada (centre) with members of the Arada and Keystone executive teams (Photo: AETOSWire) Master-planned by Foster + Partners, the vibrant new urban destination will deliver at least 5,000 homes, with half of the site dedicated to green space and a kilometre of active waterfront. Boasting unrivalled transport links, the integration of air, road, rail, river and tunnel links makes this one of the most connected sites in London. Spread over a 47-acre area – twice the size of the Hudson Yards mixed-use development in New York - Thameside West represents one of Europe’s largest and most strategi

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 12:00:00 CET | Press release

ZIIHERAplus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapyZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysisFirst Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye